Gyre Posts Q2 Revenue of $29.1M, Reaffirms Full-Year Outlook, and Flags GNI Japan Share Pledge
GYRE sits 23% above its 52-week low of $5.44.
Summary
Gyre Therapeutics reported Q2 2026 revenue of $29.1 million and a GAAP loss of $0.12 per share, reaffirmed full-year guidance, and disclosed that its controlling shareholder has pledged its Gyre shares as collateral for a loan, creating potential selling pressure.
Key Events · Earnings and Guidance · GYRE
-
Q2 Revenue and Earnings
Revenue came in at $29.1 million, down 2% year-over-year, with a GAAP loss of $0.12 per share. ETUARY sales grew, but collaboration revenue declined after the Astellas agreement ended.
-
Full-Year Guidance Reaffirmed
Management reaffirmed 2026 revenue guidance of $110 million to $115 million, implying a significant ramp in the second half.
-
Cullgen Merger Completed
The all-stock acquisition of Cullgen closed on May 4, 2026, adding targeted protein degrader assets and new management. Transaction costs of $6.9 million were incurred in H1.
-
F351 NDA Accepted by NMPA
China's NMPA accepted the New Drug Application for F351 (hydronidone) for CHB-associated liver fibrosis in May 2026, triggering a $4.9 million milestone payment to GNI Group.
Analysis · GYRE · Life Sciences
Gyre Therapeutics posted Q2 2026 revenue of $29.1 million and a GAAP loss of $0.12 per share, while reaffirming its full-year revenue guidance of $110 million to $115 million. The quarter featured the completion of the Cullgen merger, which brought in a pipeline of targeted protein degrader assets, and the NMPA's acceptance of the F351 NDA for CHB-associated liver fibrosis. However, the filing also discloses that GNI Japan, Gyre's controlling shareholder, has pledged its Gyre shares as collateral for a JPY 20 billion loan, introducing a risk of forced share sales that could pressure the stock. With $43.3 million in cash and a net loss of $32.8 million for the first half, the company's cash runway remains adequate, but the share overhang from the pledge is a new concern.
At the time of this filing, GYRE was trading at $6.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $743.6M. The 52-week trading range was $5.44 to $9.42. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.